DDInter1851 DDInter1676
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Trazodone {u} (Compound) resembles {v} (Compound) Zuclopenthixol
Trazodone {u} (Compound) resembles {v} (Compound) Quetiapine
Trazodone {u} (Compound) binds {v} (Gene) HTR2C
Trazodone {u} (Compound) palliates {v} (Disease) bipolar disorder
Trazodone {u} (Compound) downregulates {v} (Gene) PIN1
Trazodone {u} (Compound) causes {v} (Side Effect) Tachycardia
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Trazodone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Levothyroxine
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Trazodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Trazodone (Compound) resembles Zuclopenthixol (Compound)
Trazodone (Compound) resembles Quetiapine (Compound)
Trazodone (Compound) binds HTR2C (Gene)
Trazodone (Compound) palliates bipolar disorder (Disease)
Trazodone (Compound) downregulates PIN1 (Gene)
Trazodone (Compound) causes Tachycardia (Side Effect)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Trazodone may cause a minor interaction that can limit clinical effects when taken with Levothyroxine
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Quinine